Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

The objective of the study was to suppress elevated PTH levels in XLH patients.

Why It Was Studied

Hyperparathyroidism occurs frequently in X-linked hypophosphatemia (XLH) and may exacerbate phosphaturia, potentially affecting skeletal abnormalities.

Who Took Part

The age groups tagged for this paper are children, teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

PATIENTS were recruited from the investigators' clinics or referred from throughout the United States.

Data were collected in an in-patient hospital research unit.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

A time span of 1 year appears in the methods.

This was a prospective, randomized, placebo-controlled, double-blind, 1-year trial of paricalcitol, with outcomes measured at entry and 1 year later.

The intervention for this study was the use of paricalcitol or placebo for 1 year.

What Was Measured

Topics PubMed links to this paper include Alkaline Phosphatase, Bone Density Conservation Agents, Ergocalciferols, Familial Hypophosphatemic Rickets, Fibroblast Growth Factor-23, Fibroblast Growth Factors and Hyperparathyroidism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) over 1 year.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.